Nepal
Tuberculosis profile
Population  2013 28 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.6 (2.1–7.5) 17 (7.4–27)
Mortality (HIV+TB only) 0.32 (0.17–0.51) 1.2 (0.62–1.8)
Prevalence  (includes HIV+TB) 59 (27–100) 211 (99–365)
Incidence  (includes HIV+TB) 43 (39–49) 156 (139–178)
Incidence (HIV+TB only) 1.6 (0.66–1.8) 5.6 (2.4–6.4)
Case detection, all forms (%) 78 (68–87)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.8) 15 (10–23)
MDR-TB cases among notified pulmonary
TB cases
520 (310–890) 590 (390–870)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 15 099   2 228
Pulmonary, clinically diagnosed 8 367   0
Extrapulmonary 8 140   0
       
Total new and relapse 33 834    
Previously treated, excluding relapses 1 604    
Total cases notified 35 438    
Among 15 099 new cases:
409 (3%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 948 (13%) 953 (25%) 2 902
Laboratory-confirmed RR-/MDR-TB cases     477
Patients started on MDR-TB treatment     388
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 773 (11)
HIV-positive TB patients 65 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 65 (100)
HIV-positive people screened for TB 17 526  
HIV-positive people provided with IPT 665  
Treatment success rate (%)
New and relapse cases registered in 2012 91
Previously treated cases, excluding relapse, registered in 2012 77
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 72
XDR-TB cases started on second-line treatment in 2011 31
Laboratories 2013  
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 22
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 13
% Funded domestically 19%
% Funded internationally 65%
% Unfunded 16%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-01 Data: www.who.int/tb/data